[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-acute":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,84,0,25,[9,51,72,101,129,160,179,207,233,258,279,313,339,359,386,412,440,471,491,518,539,565,585,607,625],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100525407","precision-medicine-in-stroke-evolution-of-plasma-brain-derived-tau-in-acute-stroke-100525407",false,"NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 2","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[26,27,28,29,30,31,32,33],"Stroke","Stroke, Acute","Stroke, Ischemic","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Brain Ischemia","Nervous System Diseases",[26,35,36,37],"Brain injury","Biomarker","Pathophysiology","RECRUITING","2026-08-19",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":42},"2023-03-01",{"date":46,"type":22},"2027-03-31",{"name":48,"class":49},"Ludwig-Maximilians - University of Munich","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100465283","validation-of-early-prognostic-data-for-recovery-outcome-after-stroke-for-future-higher-yield-trials-100465283","NCT05338697","Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials","VERIFY","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Unilateral symptomatic stroke due to ischemia. (Note: Bilateral acute stroke is permitted if the stroke that is contralateral to the index stroke is asymptomatic).\n3. Motor deficits in the acutely affected UE, defined as a Shoulder Abduction and Finger Extension (SAFE) score ≤ 8 out of 10 points20,61 (i.e., excluding full or nearly full motor strength in both shoulder abduction and finger extension) within 48 to 96 hours of stroke onset (or time last known well).\n\n   a. Please note that, if significant imbalance is observed in SAFE score or MEP+ rates, the enrollment threshold for SAFE score may be updated with a formal study memo.\n4. Provision of signed and dated informed consent form within 24 to 96 hours of stroke onset, (or time last known well). Note: Participant is considered \"enrolled\" upon starting TMS (at least one stimulation is delivered) or starting study-specific MRI pulse sequence (at least one MRI beep occurs)\n5. Stated willingness to comply with all study procedures and availability for the duration of the study, including Day 90 visit which must occur in-person.\n6. Fluent in study approved languages (i.e., English or Spanish)\n\nExclusion Criteria:\n\n1. UE injury or conditions on paretic side that limited use prior to the stroke\n2. Legally blind\n3. Dense sensory loss on paretic side indicated by a score of 2 on NIHSS sensory item\n4. Unable to abduct the shoulder or extend the fingers of the non-paretic UE on verbal command\n5. Isolated cerebellar stroke\n6. Symptomatic stroke in any location within 30 days prior to index stroke.\n7. Co-enrollment in a trial of an intervention targeting the incident stroke (acute treatment or rehabilitation\u002Frecovery intervention) after baseline assessments for VERIFY are initiated\n8. Known or expected inability to maintain follow-up with study procedures through 90 days\n9. Cognitive or communication impairment precluding informed consent by the participant.\n10. Major medical, neurological, or psychiatric condition that would substantially affect functional status\n11. Non-cerebrovascular diagnosis associated with unlikely survival at 90 days\n12. Pregnancy\n13. Contraindication to noncontrast MRI (certain metallic implants, metallic foreign bodies or severe claustrophobia)\n14. Contraindication to TMS\n\n    1. Implanted electronic cardiac devices (e.g., Automatic Implantable Cardioverter-Defibrillator \\[AICD\\] or pacemaker)\n    2. Any electronic devices in the body at or above the level of the seventh cervical vertebra (such as cochlear implant, cortical stimulator, deep brain stimulator, vagus nerve stimulator, cervical spine epidural stimulator, or ventriculoperitoneal shunt)\n    3. Ferromagnetic intracranial metallic implant\n    4. Skull defect related to current stroke\n    5. Seizure after onset of current stroke\n    6. Seizure within the last 12 months while taking anti-epileptic medications\n    7. Previous serious adverse reaction to TMS\n15. Anticipated inability to perform study procedures within 168 hours of symptom onset\n\n    1. Unable to perform behavioral assessments within 48-120 hours of symptom onset (or time last known well).\n    2. Unable to receive TMS within 72-168 hours or get MRI within 48-168 hours of symptom onset (or time last known well).",{"count":59,"type":22},657,"VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.",[26,27,28],[56],"2026-08-18",{"date":41,"type":42},{"date":66,"type":42},"2022-06-18",{"date":68,"type":22},"2027-10",{"name":70,"class":49},"Yale University",45,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":50},"100382580","endovascular-acute-stroke-intervention---tandem-occlusion-trial-100382580","NCT04261478","Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","A Multi-centre, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Controlled Trial Comparing Cervical Internal Carotid Artery Stenting to no Stenting During Thrombectomy for Tandem Occlusion Stroke","EASI-TOC","Inclusion Criteria:\n\n* Acute ischemic anterior circulation stroke eligible for endovascular therapy according to local guidelines, with or without prior intravenous thrombolysis:\n\n  * Occlusion of the carotid terminus, M1 or M2 segments of the middle cerebral artery (MCA)\n  * A neurological deficit judged to be disabling by the patient and\u002For treating physician\n  * Any acute imaging judged by the treating physician to demonstrate salvageable brain tissue possibly amenable to EVT\n  * Groin puncture within 24-hours of onset or last known normal\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion of presumed atherosclerotic etiology on initial non-invasive vascular imaging\n* Informed consent from patient or surrogate or deferral of consent, according to local ethics policies\n\nExclusion Criteria:\n\n* Pre-existing neurological impairment (modified Rankin score ≥3)\n* Any underlying disease or condition making protocol adherence and\u002For 3-month follow-up unlikely\n* Any known contra-indication to EVT, angioplasty\u002Fstenting, or antiplatelet therapy\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion NOT confirmed on conventional angiography\n* Ipsilateral ICA stenosis or occlusion attributable to clinically or radiologically confirmed arterial dissection\n* Isolated cervical carotid occlusion without intracranial occlusion\n* Pregnancy",{"count":81,"type":22},458,"INTERVENTIONAL",[84],"NA","Patients with tandem occlusion or tandem lesion (TL), that is, stroke with an acute intracranial anterior circulation occlusion and an ipsilateral cervical ICA (c-ICA) high-grade stenosis or occlusion, constitute about 15-20% of patients undergoing endovascular thrombectomy (EVT).\n\nHowever, the optimal treatment of acute stroke patients with TL remains uncertain, as relatively few patients with TL were included in the major randomized controlled trials of EVT and management of the c-ICA was generally not specified by protocol nor analyzed post-hoc.\n\nRecent large multi-centre retrospective cases series suggest that acutely stented patients may have more favorable outcomes than patients treated with angioplasty alone or those with no acute ICA intervention, but high quality randomized trial data are lacking.\n\nEASI-TOC, a phase 3, academic multi-centre, controlled trial (PROBE design) with embedded pilot phase, will seek to determine if in patients undergoing acute intracranial thrombectomy for anterior circulation stroke with concurrent ipsilateral symptomatic high-grade (≥70%) atherosclerotic stenosis or occlusion of the extracranial ICA, endovascular ICA revascularization with stenting is superior to intracranial thrombectomy alone with regards to functional outcome at 90 days. Patients will be randomized to Acute stenting or No acute stenting (1:1 allocation).",[27,87,88],"Carotid Stenosis","Carotid Artery Diseases",[90,91,92],"Thrombectomy","Tandem occlusion","Carotid stenting","2026-08-13",{"date":95,"type":42},"2026-08-14",{"date":97,"type":42},"2020-08-31",{"date":68,"type":22},{"name":100,"class":49},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":82,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100552185","ecmo-abi-detection-with-hyperfine-100552185","NCT06469801","ECMO ABI Detection With Hyperfine","Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","Inclusion Criteria\n\n* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years\n* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO\n\n  • High risk participants include, but are not limited to:\n* Undergoing cardiac surgery\n* Congenital heart disease\n* Congenital diaphragmatic hernia\n* Refractory hypoxemic and\u002For hypercarbic respiratory failure\n* Vasoactive-refractory shock\n\nExclusion Criteria\n\n* Pregnancy\n* Any patient who has a contraindication to having an MRI\n* Patients with a passive or active implant will:\n\n  * First be reviewed on MRISafety.com to determine MR conditionality\n  * If device is listed as Conditional or Unsafe for a 1.5T or a 3T, device will then be reviewed by MRI Safety Officer or MRI Physician Section chief to determine true conditionality for the portable MRI","0 Days","17 Years",{"count":111,"type":22},40,[84],"The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.",[115,116,117,27],"Acute Brain Injury","Extracorporeal Membrane Oxygenation Complication","Hypoxia-Ischemia, Brain",[119],"Pediatric","2026-08-10",{"date":122,"type":42},"2026-08-11",{"date":124,"type":42},"2024-07-23",{"date":126,"type":22},"2027-12-01",{"name":128,"class":49},"Children's Mercy Hospital Kansas City",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":82,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100497715","bimanual-motor-skill-learning-in-acute-stroke-100497715","NCT05760846","Bimanual Motor Skill Learning in Acute Stroke","Exploring the Neural Substrates of Proximal and Distal Bimanual Motor Skill Learning Through Robotics and Multimodal Brain Imaging","MLAS4","ACUTE STROKE PATIENTS:\n\nInclusion Criteria:\n\n* acute stroke (\\\u003C 21 days)\n* aged 18-90 years\n* with a demonstrated stroke (ischemic or hemorrhagic) lesion on brain imaging\n\nExclusion Criteria:\n\n* \" classical \" contre-indication to MRI (non-MR-compatible pacemaker, pregnancy, non-MR-compatible implanted devices, claustrophobia, etc ...)\n* difficulty in understanding or executing commands\n* drug\u002Falcohol abuse\n* severe aphasia \u002F cognitive deficits interfering with study\n* inability to complete the tasks (i.e. full paralysis of the arm)\n* multiple strokes \u002F dementia \u002F psychiatric condition\n\nHEALTHY INDIVIDUALS:\n\nInclusion Criteria:\n\n• 18-90 years\n\nExclusion Criteria:\n\n* medical history with a previous stroke \u002F relevant neurological deficit\n* drug\u002Falcohol abuse\n* psychiatric condition\u002F dementia",true,"90 Years",{"count":140,"type":22},160,[84],"The subacute phase of stroke provides a window into how a lesion perturbs sensorimotor functions prior to reorganisation driven by plasticity and neurorehabilitation. The recovery from motor impairment has been extensively studied, but it is currently unknown whether motor skill learning (MSkL) is enhanced or impaired during acute stroke, especially bimanual motor skill learning (bim-MSkL), which likely requires more motor-attentional-cognitive resources than unimanual MSkL.\n\nThe goals of this project are: to determine the neural substrates critical to achieve proximal and distal bimanual motor skill learning (bim-MSkL) by specifying whether (sub)acute stroke to different brain areas (cortical and subcortical) induce specific deficits in bimanual and\u002For distal bim-MSkL, which behavioral components are involved in bim-MSkL, and whether damage to the motor, sensory and inter-hemispheric pathways specifically impairs proximal and\u002For distal bim-MSkL.",[27,144],"Stroke, Subacute",[146,147,148,149,150],"Motor Skill Learning","Upper limb","Acute stroke","Rehabilitation","Subacute stroke",{"date":152,"type":42},"2026-08-12",{"date":154,"type":42},"2023-04-17",{"date":156,"type":22},"2028-10",{"name":158,"class":49},"University Hospital of Mont-Godinne",2,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":137,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":166,"targetDuration":4,"studyType":82,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":159},"100375696","exploring-motor-learning-in-acute-stroke-through-robotics-100375696","NCT04171856","Exploring Motor Learning in Acute Stroke Through Robotics","ACUTE STROKE PATIENTS:\n\nInclusion Criteria:\n\n* acute stroke (\\> 21 days)\n* aged 18-90 years\n* with a stroke lesion on brain imaging\n\nExclusion Criteria:\n\n* \" classical \" contre-indication to MRI (non-MR-compatible pacemaker, pregnancy, non-MR-compatible implanted devices, claustrophoby, etc ...)\n* difficulty in understanding or executing commands\n* drug\u002Falcohol abuse\n* severe aphasia \u002F cognitive deficits interfering with study\n* inability to voluntarily move the affected arm (i.e. complete paralysis of the arm)\n* multiple strokes \u002F dementia \u002F psychiatric condition\n\nPATIENTS WITH TRANSIENT GLOBAL AMNESIA:\n\nClinical diagnosis, criteria of Hodge \\& Warlow (1990):\n\n* Anterograde amnesia observed by a witness\n* No alteration of consciousness or loss of identity\n* Cognitive dysfunction limited to amnesia\n* Lack of focused neurological deficit or argument for a comitiality\n* Absence of head trauma\n* Symptom resolution within 24 hours\n* Possible existence of vegetative symptoms\n\nInclusion criteria:\n\n* Transient global amnesia\n* 8-90 years old\n* Be able to perform 3 consecutive sessions on a rehabilitation robot\n\nExclusion criteria:\n\n* Severe aphasia \u002F cognitive deficits interfering with study\n* Psychiatric disorders\n* Alcohol \u002F drug addiction\n* Exclusion criteria related to MRI\n\nHEALTHY INDIVIDUALS:\n\nInclusion Criteria:\n\n• 18-90 years\n\nExclusion Criteria:\n\n* medical history with a previous stroke\u002Fneurological deficit\n* drug\u002Falcohol abuse\n* psychiatric condition\u002F dementia\n\nCHRONIC STROKE PATIENTS:\n\nInclusion Criteria:\n\n* chronic stroke (\\>6 months)\n* aged 18-90 years\n* with a stroke lesion on brain imaging\n\nExclusion Criteria:\n\n* difficulty in understanding or executing commands\n* drug\u002Falcohol abuse\n* severe aphasia \u002F cognitive deficits interfering with study\n* inability to voluntarily move the affected arm (i.e. complete paralysis of the arm)\n* multiple strokes \u002F dementia \u002F psychiatric condition",{"count":167,"type":22},245,[84],"The acute phase of stroke is characterized by an enhancement of neural plasticity which supports rapid motor recovery. It is unclear whether acute stroke patients can acquire new motor skills with their affected upper limb. The aims of this research program are:\n\n1. To test the capacity of acute stroke patients (\\\u003C 21 days) to learn and retain a complex unimanual motor skill.\n2. To explore whether acute stroke to different brain regions (quantified with brain MRI) induces specific deficits in motor skill learning.\n3. To compare acute stroke patients with healthy individuals and with chronic stroke patients.",[27],[148,172,147,149,150],"Motor skill learning",{"date":152,"type":42},{"date":175,"type":42},"2020-01-01",{"date":177,"type":22},"2040-07-01",{"name":158,"class":49},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":82,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100550097","mystroke-for-stroke-survivors-and-caregivers-100550097","NCT06442631","MyStroke for Stroke Survivors and Caregivers","An Individualized Video-based Stroke Education Platform for Stroke Survivors and Caregivers","Inclusion Criteria:\n\n* At least 18 years old\n* Admitted to hospital with clinical diagnosis of acute ischemic stroke (imaging confirmation not required)\n* Stroke symptom onset within 30 days of enrollment\n* Being discharged to either home or an acute rehabilitation facility\n* Access to internet enabled device (smartphone, tablet, computer)\n* Fluent in either English or Spanish (does not need to be native or primary language)\n* Willingness and ability to sign informed consent\n\nExclusion Criteria:\n\n* Severe aphasia (score of ≥2 on NIHSS item 9)\n* Ischemic stroke that is attributed to a surgical procedure\n* Resides in a skilled nursing facility prior to admission\n* Being discharged to skilled nursing facility or long-term acute care facility\n* Unwillingness or inability to participate in remote\u002Fvirtual study visits\n* A terminal or advanced condition that raises the possibility the subject may not survive 90 days\n* Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study",{"count":187,"type":22},690,[84],"The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:\n\n1. Does a personalized, video-based educational platform improve stroke knowledge?\n2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?\n3. Do different strategies of nudging improve engagement with educational material after hospital discharge?\n\nIn order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:\n\n1. Receive standard education during the stroke hospitalization\n2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.\n3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.\n4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.",[27,191],"Ischemic Stroke, Acute",[193,194,195],"stroke education","ischemic stroke","stroke knowledge","NOT_YET_RECRUITING","2026-07-29",{"date":199,"type":42},"2026-07-31",{"date":201,"type":22},"2026-08-01",{"date":203,"type":22},"2030-03-01",{"name":205,"class":49},"University of Pennsylvania",5,{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":50},"100468304","doac-in-chinese-patients-with-atrial-fibrillation-100468304","NCT05378035","DOAC in Chinese Patients With Atrial Fibrillation","Direct Oral Anticoagulant Levels in Chinese Patients With Atrial Fibrillation - A Real- World Pharmacokinetic Study","DOAC-REAL","Inclusion Criteria:\n\n* Chinese nonvalvular atrial fibrillation (NVAF) patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more.\n* Patients aged 18-80 years old.\n* Patients who are able to provide an informed consent.\n* Patients who are indicated for elective medical procedures that require interruption of direct oral anticoagulants (DOAC) for 48 hours.\n\nExclusion Criteria:\n\n* Patients who developed thromboembolism (e.g. ischemic stroke, ischemic bowel, etc.) or major systemic bleeding (e.g. intracerebral haemorrhage, gastrointestinal bleeding) during DOAC usage.\n* Patients with creatinine clearance by Cockroft-Gault formula ≤ 30 mL\u002Fmin.\n* Patients with inappropriate DOAC dosages with respect to age, body weight, and creatinine clearance.\n* Patients who receive DOAC with indications other than NVAF, such as history of mitral stenosis, metallic heart valve, thrombophilia, venous thromboembolism, etc.\n* Patients with conditions that alter haemostasis besides DOAC use, such as essential thrombocytosis, hepatic congestion, hepatic failure with coagulopathy, etc.","80 Years",{"count":217,"type":22},427,"Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, and rivaroxaban - were shown to reduce the risk of major bleeding compared to warfarin. The predictable pharmacokinetic profiles of DOACs also favour their use over warfarin. Together with increasing AF incidence due to population ageing, increased AF detection, and territory-wide reimbursement schemes, DOAC prescriptions have been surging worldwide. In Hong Kong, more than 78,354 patients received DOAC from January 2009 through April 2021 according to the Hospital Authority registry.\n\nThe more liberal use of DOACs has led to new issues that require a thorough understanding of ethnic-specific DOAC pharmacokinetic profiles. For instance, 12- 15% of anticoagulated patients annually required interventional procedures that involve temporary discontinuation of DOAC for 48 hours or more. Although guideline-based periprocedural DOAC interruption resulted in a low 30-day thromboembolism rate of 0.16% - 0.6% in a Caucasian cohort, same measures for elective colonoscopies in a local population-based study resulted in a 30-day periprocedural thromboembolism rate of up to 2.2%. Although these studies cannot be compared directly, the remarkable interethnic discrepancy between the two cohorts warrants further pharmacokinetic and pharmacogenomic studies. More importantly, quantifying residual DOAC levels during the interruption periods may imply on duration of periprocedural DOAC interruption, length of hospital-stay, and the risk of thromboembolic and bleeding complications.\n\nMapping inter- and intra-individual variations in DOAC levels may also impact on the management of ischemic stroke among DOAC recipients. Epidemiological studies have shown alarmingly up to 13% of acute ischemic stroke patients were on anticoagulation prior to stroke onset with increasing number of DOAC. These patients received low rates of recanalization therapy due to apprehension of bleeding complications, thus compromised survival and neurological recovery. A prospective study that reveals Asian-specific DOAC pharmacokinetic profiles may inform cross-disciplinary, territory-wide periprocedural care and acute stroke intervention strategy for the rapidly expanding DOAC population.",[220,26,27,30,221,222,223],"Atrial Fibrillation","Major Adverse Cardiovascular Event","Arterial Thromboembolism","Venous Thromboembolism","2026-07-28",{"date":226,"type":42},"2026-07-30",{"date":228,"type":42},"2022-09-28",{"date":230,"type":22},"2027-12-31",{"name":232,"class":49},"Chinese University of Hong Kong",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":82,"phases":242,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100648039","phase-3-normobaric-hyperoxia-with-extended-window-endovascular-therapy-for-acute-ischemic-stroke-opens-extend-100648039","NCT07717216","Normobaric Hyperoxia With Extended-Window Endovascular Therapy for Acute Ischemic Stroke (OPENS-EXTEND)","Efficacy and Safety of Periprocedural Normobaric Hyperoxia With Endovascular Therapy for Acute Ischemic Stroke 6-24 Hours After Last Known Well: A Multicenter Randomized Sham-Controlled Phase 3 Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Clinical signs and symptoms consistent with acute anterior-circulation ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater at the time of randomization.\n3. Pre-stroke modified Rankin Scale (mRS) score of 0 or 1.\n4. Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 6 or greater on baseline non-contrast computed tomography or diffusion-weighted magnetic resonance imaging.\n5. Eligible for endovascular therapy according to current guideline-recommended clinical practice and the judgment of the treating stroke team and neurointerventional team.\n6. Randomization can be completed between 6 and 24 hours after the time the participant was last known well. Randomization and initiation of the study intervention must not cause an avoidable delay in endovascular therapy.\n7. Pre-procedural computed tomography angiography or magnetic resonance angiography confirms large-vessel occlusion consistent with the participant's neurological deficits, involving one of the following: internal carotid artery or M1 segment of the middle cerebral artery.\n8. Baseline level of consciousness score on item 1a of the NIHSS is 0 or 1.\n9. Written informed consent has been obtained from the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* General Exclusion Criteria\n\n  1. NIHSS score of less than 10 at the time of randomization; substantial neurological improvement such that the participant is no longer considered eligible for endovascular therapy; or imaging-confirmed spontaneous recanalization with no remaining treatable target-vessel occlusion.\n  2. Seizure at stroke onset when the current neurological deficits are considered primarily attributable to a postictal state, or when a reliable baseline NIHSS assessment cannot be obtained.\n  3. Active clinically significant bleeding or a bleeding diathesis that, in the judgment of the investigator or treating clinical team, makes endovascular therapy or participation in the study unsafe.\n  4. Platelet count below 100 × 10⁹\u002FL.\n  5. Clinically significant coagulation abnormality, anticoagulant exposure, or coagulation-factor deficiency that, according to the local standard of care at the participating center, makes the participant ineligible for endovascular therapy.\n  6. Severe or end-stage cardiac, hepatic, or renal dysfunction that is expected to substantially affect 90-day survival, functional outcome assessment, or the safety of study participation.\n  7. Persistent baseline blood glucose below 50 mg\u002FdL (2.78 mmol\u002FL) or above 400 mg\u002FdL (22.20 mmol\u002FL) after appropriate initial evaluation or correction.\n  8. Persistent systolic blood pressure above 185 mmHg or diastolic blood pressure above 110 mmHg despite appropriate antihypertensive treatment.\n  9. Life expectancy of less than 90 days because of a pre-existing disease or other underlying medical condition.\n  10. Known pregnancy.\n  11. Any of the following clinically significant respiratory diseases or conditions that, in the investigator's judgment, may make high-concentration oxygen therapy unsafe or interfere with reliable administration of the study intervention:chronic obstructive pulmonary disease; acute pulmonary infection; acute respiratory distress syndrome;clinically significant pleural effusion;chronic hypercapnic respiratory failure; another respiratory condition that may affect the safety of high-concentration oxygen therapy or the administration of the mask-based intervention.\n  12. Any of the following conditions before randomization: requirement for supplemental oxygen at a flow rate greater than 3 L\u002Fmin to maintain peripheral oxygen saturation above 94%;requirement for noninvasive ventilatory support because of respiratory failure; or requirement for invasive mechanical ventilation because of respiratory failure.\n  13. Persistent clinically significant vital-sign instability after initial treatment, including but not limited to: heart rate of 50 beats per minute or lower or 120 beats per minute or higher; peripheral oxygen saturation of 90% or lower;respiratory rate of 10 breaths per minute or lower or 30 breaths per minute or higher; or other unstable vital signs considered by the investigator to potentially compromise participant safety.\n  14. Active vomiting, a high risk of aspiration, or inability to tolerate the study mask, except for participants who require clinically indicated endotracheal intubation and mechanical ventilation.\n  15. Active gastrointestinal bleeding.\n  16. History of a severe adverse reaction to iodinated contrast media that cannot be adequately managed with premedication, an alternative contrast strategy, or other appropriate clinical measures and therefore precludes endovascular therapy.\n  17. Current participation in another interventional clinical trial that may interfere with the study intervention, safety assessment, or evaluation of study outcomes.\n  18. Any other disease, condition, or circumstance that, in the investigator's judgment, makes the participant unsuitable for the study or may interfere with study treatment, participant safety, or outcome assessment. The specific reason must be documented.\n* Imaging Exclusion Criteria\n\n  1. Evidence of intracranial hemorrhage on baseline computed tomography or magnetic resonance imaging, including but not limited to intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or epidural hemorrhage.\n  2. Failure to meet the prespecified perfusion-mismatch imaging criteria, including an ischemic core volume of 70 mL or greater.\n  3. Pre-randomization computed tomography angiography or magnetic resonance angiography demonstrates abnormal vascular anatomy or excessive vascular tortuosity such that, in the judgment of the treating neurointerventionalist, the target vessel cannot be safely accessed with endovascular devices or endovascular therapy is technically infeasible.\n  4. Based on the medical history, computed tomography angiography, magnetic resonance angiography, or other imaging findings, any of the following is suspected to be the primary cause of the index stroke and is considered to make endovascular therapy inappropriate or unsafe: cerebral vasculitis; aortic dissection; cervical arterial dissection; or intracranial arterial dissection.\n  5. Intracranial vascular occlusions involving multiple independent vascular territories, bilateral anterior-circulation infarction, or simultaneous anterior- and posterior-circulation infarction.\n\n     A tandem lesion consisting of cervical internal carotid artery occlusion together with an intracranial large-vessel occlusion in the same vascular territory will not be automatically excluded if the treating neurointerventionalist considers endovascular therapy appropriate.\n  6. Confirmed moyamoya disease or moyamoya syndrome.\n  7. Substantial cerebral edema, mass effect, or midline shift on baseline computed tomography or magnetic resonance imaging.\n  8. Intracranial neoplasm that may affect the 90-day functional outcome, increase the risk of hemorrhage, or interfere with study assessment. A small, asymptomatic meningioma may be permitted at the investigator's discretion.",{"count":241,"type":22},314,[243],"PHASE3","Although endovascular therapy (EVT) has substantially improved recanalization rates and extended the treatment window for acute ischemic stroke, fewer than half of patients achieve functional independence despite successful reperfusion. Growth of the ischemic core before reperfusion and ischemia-reperfusion injury after recanalization may contribute to unfavorable outcomes. Therefore, an adjunctive neuroprotective strategy that preserves the ischemic penumbra before and during EVT may further improve clinical outcomes.\n\nNormobaric hyperoxia (NBO) is a noninvasive and readily available treatment that delivers high-concentration oxygen at normal atmospheric pressure. By increasing oxygen delivery to hypoperfused but potentially salvageable brain tissue, NBO may delay infarct growth, preserve the blood-brain barrier, and reduce reperfusion injury. Previous preclinical studies and early clinical trials have suggested that NBO may provide neuroprotection without increasing oxidative stress or other major safety risks. The previous OPENS-1 and OPENS-2 trials showed that periprocedural NBO combined with EVT reduced infarct volume and improved 90-day functional outcomes in patients treated within 6 hours after stroke onset. In addition, a preliminary two-center study involving 120 patients treated 6-24 hours after onset suggested greater early neurological improvement and a potentially favorable 90-day functional outcome with NBO plus EVT compared with EVT alone.\n\nOPENS-EXTEND is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of periprocedural NBO as an adjunct to EVT in patients with acute ischemic stroke caused by anterior-circulation large-vessel occlusion who present 6-24 hours after symptom onset or last known well and have imaging evidence of salvageable ischemic brain tissue. Participants will be randomly assigned to receive either EVT combined with NBO or EVT with standard medical management alone. The primary hypothesis is that adjunctive NBO will improve functional outcomes at 90 days without increasing safety risks.",[27,246,247,248],"Neuroprotection","Normobaric Hyperoxia","Endovascular Treatment","2026-07-17",{"date":251,"type":42},"2026-07-21",{"date":253,"type":22},"2026-09-01",{"date":255,"type":22},"2029-09-01",{"name":257,"class":49},"Weifang Medical University",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":82,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":50},"100624584","individual-vs-co-treatment-in-acute-stroke-rehabilitation-and-evaluation-100624584","NCT07411534","Individual vs Co-Treatment in Acute Stroke Rehabilitation and Evaluation","ICARE","Inclusion Criteria:\n\n* Inpatient admission to the neurology stroke service AND\n* Orders placed for both PT and OT within 96 hours of hospital admission\n\nExclusion Criteria:\n\n* Patient is known to be \\\u003C18 years\n* Patient is known to be a prisoner\n* Patient is known to be pregnant\n* Prior evaluation or treatment by PT and\u002For OT while admitted under the stroke service before study enrollment\n* Clinician determines that either individual PT and OT or co-treatment is required or contraindicated for the optimal care of the patient",{"count":266,"type":22},567,[84],"This is a single center, pragmatic, randomized trial comparing the effectiveness of two commonly used approaches (co-treatment and individual treatment) in acute care rehabilitation.",[26,270],"Stroke Acute","2026-07-14",{"date":273,"type":42},"2026-07-16",{"date":253,"type":22},{"date":276,"type":22},"2027-12-28",{"name":278,"class":49},"Vanderbilt University Medical Center",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":287,"targetDuration":289,"studyType":23,"phases":4,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100635512","master-study-protocol-for-the-cohort-of-the-specialist-network-stroke-sn-strokestroke-core-100635512","NCT07553650","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke) (Stroke-CORE)","Stroke-CORE","Inclusion Criteria:\n\n* Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH\n* Hospital admission \\\u003C24h after symptom onset\n* Age 18+ years for the basic Modules AIS and ICH; age \\\u003C18 years for the basic Module paediatric stroke patients\n* Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves\n* Additional inclusion criteria are defined by the individual Modules\n\nExclusion Criteria:\n\n* In-hospital stroke\n* TIA\n* SAH\n* Stroke as a complication of a medical procedure\n* Enrolment in a randomised placebo-controlled interventional trial\n* Already enrolled in the SN STROKE base cohort",{"count":288,"type":22},12750,"90 Days","The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study.\n\nIn addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies.\n\nThe study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration.\n\nAs part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods.\n\nThe study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.",[292,293,270,26,294],"Intracerebral Haemorrhage","Paediatric Stroke","Ischemic Stroke",[26,194,296,293,29,30,297,298,299,300,301,302],"Intracerebral Hemorrhage","Vascular Diseases","Cardiovascular Diseases","Brain Infarction","Embolic Stroke","Thrombotic Stroke","Acute","2026-07-07",{"date":305,"type":42},"2026-07-09",{"date":307,"type":22},"2026-07-27",{"date":309,"type":22},"2030-06-30",{"name":311,"class":49},"Charite University, Berlin, Germany",12,{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":82,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":336,"locationsCount":338},"100540311","stroke-alarm-efficacy-trial-100540311","NCT06315192","Stroke Alarm Efficacy Trial","StrokeAlarmEFF","INCLUSION CRITERIA\n\n1. Age 50 years or older\n2. Modified Rankin scale of 0-2.\n3. Diagnosed with either:\n\n   A. Recent\\* transient ischemic attack (TIA, G45.9), AND:\n   * ABCD2 score of ≥6, OR:\n   * Atrial fibrillation OR:\n   * Large artery atherosclerosis\\*\\*.\n\n   B. Recent\\* acute ischemic stroke (I63), AND:\n\n   • Atrial fibrillation, OR:\n   * Large artery atherosclerosis\\*\\*. C. Atrial fibrillation\u002Fflutter (I48), AND\n   * None, or reduced dose of, oral anticoagulation medication\\*\\*\\*, AND\n   * CHA2DS2-VASC score ≥4.\n\n   D. Recent\\* intracerebral hemorrhage (I61.9), AND:\n\n   • Atrial fibrillation.\n4. The patient has received the required information about the study and agrees in writing to participate.\n5. Smartphone user since at least 1 year.\n\n   * Within the last 2 weeks \\*\\*Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.\n\n     * Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.\n\nEXCLUSION CRITERIA\n\n1. Previous inclusion in this study.\n2. Arm motor deficit from any previous medical condition.\n3. Unable to give informed consent to participate in the study.\n4. Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.\n5. Does not have access to a Stroke Alarm compatible smartphone.\n6. Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.\n7. Does not want to participate.",{"count":321,"type":22},500,[84],"The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.\n\nThis is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.\n\nA total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.\n\nPatients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.\n\nPatients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:\n\n1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR\n2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR\n3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR\n4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.\n\nA control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a\u002F5b 1-4), presence of neglect\u002Finattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.",[270,220,325],"TIA",[26,327,328,329],"wearable","indication","sensor","2026-06-29",{"date":332,"type":42},"2026-06-30",{"date":334,"type":42},"2024-09-05",{"date":230,"type":22},{"name":337,"class":49},"Region Skane",10,{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":82,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":50},"100622097","phase-3-hr-mri-directed-tirofiban-therapy-for-late-window-acute-ischemic-stroke-tian-100622097","NCT07379190","HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;\n3. Time from symptom onset or last known normal state to randomization: \\> 24 hours and ≤ 7 days;\n4. Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;\n5. Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;\n6. Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；\n2. Intracranial hemorrhage confirmed by computed tomography (CT)；\n3. Definite or suspected cardiogenic embolism；\n4. History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；\n5. Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；\n6. Imaging examinations indicating that the area of the current cerebral infarction exceeds 1\u002F2 of the area of a single cerebral lobe;\n7. Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;\n8. History of hypersensitivity to aspirin;\n9. Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);\n10. Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin or serum creatinine \\[Cr\\] \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), or severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\> 2 times the upper limit of normal \\[ULN\\], or serum aspartate aminotransferase \\[AST\\] \\> 2 times the ULN);\n11. Severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV);\n12. Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \\\u003C 6 months;\n13. Concurrent new cerebral infarction in both anterior and posterior circulations;\n14. Inability to complete the follow-up procedures;\n15. Presence of other known neurological disorders that may complicate the follow-up;\n16. Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up;\n17. Other conditions that the investigators consider inappropriate for enrollment in this study.",{"count":81,"type":22},[243],"This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.",[27,28,350],"Cerebral Infarction","2026-06-24",{"date":353,"type":42},"2026-06-25",{"date":355,"type":42},"2026-06-22",{"date":357,"type":22},"2029-05-01",{"name":257,"class":49},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":82,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":50},"100612460","comperative-effects-of-transcutaneous-auricular-and-cervical-vagus-nerve-stimulation-in-subacute-stroke-patients-100612460","NCT07253870","Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients","Comparative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation on Upper Limb Function, Cognition and Quality of Life in Subacute Stroke Patients","Inclusion Criteria:\n\n* First ever ischemic stroke\n* Subacute phase of stroke 3-6 months post onset\n* Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores ranged from 20 - 50\n\nExclusion Criteria:\n\n* Previous injury or surgical intervention of vagus nerve\n* Patients with cardiac arrest and arrythmias\n* Uncontrolled hypertension\n* Apraxia\n* Other neurologic or musculoskeletal diseases\n* Presence of implanted electronic devices","45 Years","70 Years",{"count":369,"type":22},54,[84],"This study aims to determine whether transcutaneous vagus nerve stimulation (tVNS) via auricular or cervical branches enhances recovery when combined with task-specific training in subacute stroke patients. We anticipate finding that both stimulation methods may improve upper limb motor function compared to conventional therapy. The research is expected to reveal specific cognitive domains (attention, memory, executive function) that benefit most from each stimulation approach, while also demonstrating meaningful improvements in patients' quality of life measures. These findings may make a significant practical contribution by providing clinicians with evidence-based guidance on suitable tVNS approach for improving functional independence and quality of life for stroke survivors.",[26,27],[374,375,376],"Task Specific Training","Upper Limb Function","Cognition","2026-06-17",{"date":379,"type":42},"2026-06-18",{"date":381,"type":42},"2025-11-20",{"date":383,"type":22},"2026-06-20",{"name":385,"class":49},"Lahore University of Biological and Applied Sciences",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":82,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":50},"100639678","ivr-on-upper-limb-rehabilitation-in-stroke-patients-a-clinical-trial-100639678","NCT07609966","IVR ON UPPER-LIMB REHABILITATION IN STROKE PATIENTS: A CLINICAL TRIAL","Impact of Immersive Virtual Reality in the Rehabilitation in the Acute Phase of Stroke: a Clinical Study and Correlation With Blood Biomarkers and Polymorphisms Related to Neuroplasticity","REVICTUS","Inclusion Criteria: Diagnosis of ischemic stroke or intracerebral hemorrhage. Age \\> 18 years. \\\u003C 7 days between stroke onset and inclusion in the study. Impairment of mobility in the right or left upper limb due to stroke. After hospital discharge, patients continue an intensive conventional rehabilitation (ICR) program at their referral rehabilitation center (MUTUAM).\n\nAbility to understand and sign the study informed consent form (ICF) and the IDIBGI Biobank informed consent form.\n\n\\-\n\nExclusion Criteria:\n\nPrevious upper limb disability (neurological or non-neurological cause). Previous dementia or any disease with a life expectancy of less than 1 year. Language comprehension difficulties. Difficulty remembering exercise instructions. History of photosensitive epilepsy.\n\n\\-",{"count":395,"type":22},120,[84],"Stroke is the leading cause of acquired disability in adults. Neurorehabilitation aims to recover the affected function by stimulating neuroplasticity. Immersive virtual reality (IVR) has shown that it can be effective but the evidence is still weak. Similarly, few studies have analysed blood biomarkers as outcome or predictive indicators, and knowledge of the influence of genetic polymorphisms on rehabilitation efficacy is limited. Our objectives are (1) to demonstrate that the addition of IVR to conventional rehabilitation (CR) improves upper-limb motor function, functional status, and quality of life in stroke patients, at short and long term; (2) to determine the effect of IVR on the expression of neuroplasticity biomarkers at long term; (3) to evaluate the impact of genetic polymorphisms on the rehabilitation and functional prognosis of treated patients, at short and long term; and (4) to identify acute phase predictive biomarkers of motor recovery and functional prognosis at short and long term. To this end, we propose a single-center, prospective, randomised, controlled, and open label clinical trial with blinded end-point assessment. Adults diagnosed of acute ischaemic\u002Fhaemorrhagic stroke with mobility impaired in the upper-limb and included in a program of intensive CR (ICR) at hospital discharge will be included. Patients will be randomly assigned into two groups: ICR+IVR or only ICR and will be followed for one year to assess, at 3 and 12 months, motor strength in the upper-limb, functional dependence and quality of life. In blood samples obtained at admission (baseline) and at 12 months, proteins and microRNAs will be analysed to identify predictive biomarkers of recovery (motor and functional) and to determine the effect of IVR on neuroplasticity mechanisms. Genetic polymorphisms that may affect motor and functional recovery of patients treated with RC±RVI will also be analysed",[270],[400,401,402],"stroke","virtual reality","rehabilitation","2026-05-20",{"date":405,"type":42},"2026-05-27",{"date":407,"type":42},"2022-08-31",{"date":409,"type":22},"2026-06",{"name":411,"class":49},"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":82,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":439},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":421,"type":22},900,[84],"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[27,191,425],"Hemorrhagic Stroke",[427,428,429,430],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":403,"type":42},{"date":434,"type":42},"2024-10-17",{"date":436,"type":22},"2028-07-31",{"name":438,"class":49},"University of Chicago",8,{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":450,"conditions":451,"keywords":456,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":50},"100611983","evaluation-and-optimization-of-telephone-triage-using-artificial-intelligence-ai-models-for-the-detection-of-demands-for-time-dependent-pathology-at-the-emergency-and-urgent-care-coordination-center-ccue-100611983","NCT07247669","Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).","Proyecto \"trIAje\": evaluación y optimización Del Triaje telefónico Mediante Modelos de Inteligencia Artificial (IA) Para la detección de Demandas Por patología Tiempo-dependiente en el Centro Coordinador de Urgencias y Emergencias (CCUE).","TrIAje Project","Inclusion Criteria:\n\nTelephone calls recorded with codes A36 + A58 (unconsciousness\u002Fcardiorespiratory arrest), A16 (respiratory distress), A23 (non-traumatic chest pain) and A54 (stroke).\n\nExclusion Criteria:\n\n* Demands with relevant information about the patient or the event incomplete or absent.",{"count":449,"type":22},5000000,"Improving Telephone Triage in Emergency Calls with AI The Coordinating Centre for Urgencies and Emergencies in Andalusia (CCUE) handles thousands of calls every day. Each call needs to be assessed based on the information given over the phone to determine how serious the case is. The reasons for calling range from minor health issues to life-threatening emergencies like cardiac arrest (CPA).\n\nThis project focuses on improving telephone triage for four key emergency situations that often indicate severe or life-threatening conditions:\n\nUnconsciousness \u002F Cardiac arrest Difficulty breathing Chest pain (non-traumatic, possible heart-related issues) Stroke symptoms Our goal is to make telephone triage more accurate and efficient by using advanced Artificial Intelligence (AI) techniques, including Machine Learning (ML) and Natural Language Processing (NLP). These tools will help CCUE operators make better and faster decisions, ensuring that patients receive the right care as quickly as possible.\n\nHow it will be done:\n\nThe investigators will analyze anonymized historical call data from the emergency coordination system (CCR) and digital clinical records (HCDM). This includes:\n\nStructured data: Predefined fields, such as answers to standard triage questions.\n\nUnstructured data: Free-text notes and other information recorded during the call.\n\nA hybrid AI approach will be used, combining:\n\nTraditional AI methods (supervised learning and deep learning) to classify cases.\n\nGenerative AI techniques (advanced language models) to extract useful insights from free-text data.\n\nBuilding the Best Prediction Model\n\nTo find the most effective AI model, we will test different machine learning techniques, including:\n\nDecision Trees Random Forests Support Vector Machines (SVM) XGBoost Ensemble methods Neural Networks We will also analyze which questions and variables are the most important in predicting the severity of a case. Based on this, we will suggest improvements to the current triage questions to enhance accuracy.\n\nMeasuring Success\n\nWe will evaluate the AI model using key performance metrics, including:\n\nAccuracy (overall correctness) Sensitivity (ability to detect real emergencies) Specificity (ability to avoid false alarms) False Positive \\& False Negative Rates (how often the system makes mistakes) Likelihood Ratios (how well the system distinguishes between urgent and non-urgent cases) F1-Score \\& ROC Curve (overall performance indicators) Why This Matters This project will assess how effective the current telephone triage system is and develop a new AI-powered model to improve it. The goal is to help emergency operators quickly identify the most serious cases, reducing response times and improving patient outcomes. In the future, the investigators aim to integrate this improved AI model into the CCUE system to enhance emergency response across Andalusia.",[452,270,453,454,455],"Chest Pain","Respiratory Failure","Cardiac Arrest (CA)","Coma",[457,458,459,460,461,462],"Emergency Medical Communication Center","Triage Telephone","Emergency Medical Services","Priority","Machine Learning","Artificial Intelligence","2026-05-12",{"date":465,"type":42},"2026-05-13",{"date":467,"type":42},"2025-03-01",{"date":230,"type":22},{"name":470,"class":49},"Centro de Emergencias Sanitarias 061 Andalucía",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":7},"100509295","treatment-with-endovascular-intervention-for-stroke-patients-with-existing-disability-100509295","NCT05911568","Treatment With Endovascular Intervention for STroke Patients With Existing Disability","TESTED","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset\n3. Presenting to study hospital within 24 hours of last known well time\n4. Diagnosis of acute ischemic stroke\n5. Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram\n6. Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4\n7. Presenting NIH Stroke Scale score ≥6\n8. Informed consent from patient if competent or from legally authorized representative\n\nExclusion Criteria:\n\n1. Known diagnosis of a terminal cancer or terminal illness at the time of stroke\n2. Assessment of pre-stroke functional status cannot be performed during the hospital stay\n3. Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)",{"count":479,"type":22},1060,"TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.",[26,27,28],"2026-04-14",{"date":484,"type":42},"2026-04-15",{"date":486,"type":42},"2023-11-16",{"date":488,"type":22},"2028-04-15",{"name":490,"class":49},"University of Cincinnati",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":82,"phases":501,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":50},"100566670","phase-3-efficacy-and-safety-of-tenecteplase-bridging-mechanical-thrombectomy-for-acute-large-vessel-occlusion-stroke-100566670","NCT06658197","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial","TNK-LVO","Inclusion Criteria:\n\n1. Age is ≥18 years.\n2. AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes).\n3. Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA).\n4. Prestroke mRS score ≤2.\n5. Informed consent from the patient or legally authorised representative.\n\nExclusion Criteria:\n\n1. Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.) or other related conditions identified by CT.\n2. Contraindication to imaging examinations involving contrast agent injection.\n3. Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3).\n4. History of intracranial hemorrhage.\n5. History of severe head trauma or stroke within the past 3 months.\n6. Intracranial or intraspinal surgery within the past 3 months.\n7. Major surgery within the past 2 weeks.\n8. Gastrointestinal or urinary tract bleeding within the past 3 weeks.\n9. Intracranial tumor, arteriovenous malformation, or giant intracranial aneurysm.\n10. Active visceral bleeding.\n11. Aortic arch dissection.\n12. Arterial puncture at a non-compressible site within the past week.\n13. Uncontrolled hypertension despite active antihypertensive treatment: Systolic Blood Pressure \\> 180 mmHg or Diastolic Blood Pressure \\> 100 mmHg.\n14. Acute hemorrhagic tendency, including platelet count \\\u003C 100 × 10⁹\u002FL or other conditions.\n15. Heparin treatment received within the past 24 hours.\n16. For patients on oral anticoagulants: INR \\> 1.7 or PT \\> 15 seconds.\n17. Use of direct thrombin inhibitors or direct Factor Xa inhibitors within the past 48 hours.\n18. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n19. Hypodensity affecting \\> 1\u002F3 of the middle cerebral artery territory or an equivalent proportion of the basilar artery territory on non-contrast CT.\n20. Rapidly improving symptoms as determined by the investigator.\n21. Participation as a subject in another research study within the past 30 days.\n22. Any terminal illness where life expectancy is considered not to exceed 1 year.\n23. Any condition where, in the judgment of the investigator, the study treatment might pose a risk to the patient or affect the patient's participation in the study.\n24. Pregnant women.\n25. Known allergy to the active ingredients (Alteplase, Tenecteplase) or any excipients.",{"count":500,"type":22},850,[243],"A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.",[28,27,504,505],"Thrombosis, Brain","Drug Effect",[507,508],"Ischemic stroke","Tenecteplase","2026-04-08",{"date":511,"type":42},"2026-04-09",{"date":513,"type":42},"2025-12-25",{"date":515,"type":22},"2027-06-01",{"name":517,"class":49},"Xuanwu Hospital, Beijing",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":524,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":82,"phases":527,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":50},"100316605","wearable-mci-to-reduce-muscle-co-activation-in-acute-and-chronic-stroke-100316605","NCT03401762","Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke","Inclusion Criteria:\n\nChronic stroke participants\n\n* Hemiparesis from first ever stroke at least 6 months prior to screening\n* Severe motor impairment (FMA of 7-30)\n* At least some voluntary shoulder and elbow muscle activation.\n\nAcute stroke participants\n\n* Hemiparesis from first ever stroke within the past 21 days\n* Severe motor impairment (FMA of 3-20), or total Manual Motor Score of 1-8 combined in Shoulder Abduction and Finger Extensors\n\nExclusion Criteria:\n\n* Cognitive impairment with at least moderately impaired attention, or unable to follow instructions of the MCI task\n* Visual impairment (such as hemianopia) preventing full view of the screen\n* Anesthesia or neglect in the affected arm, or visual hemineglect (score of 2 on the NIH Stroke Scale Extinction and Inattention subtest).\n* Participation in another study on the affected arm within 6 weeks of enrollment or any pharmacological study\n* Inability to understand or follow commands in English due to aphasia or other reason\n* Diffuse or multifocal infarcts\n* Substantial arm pain preventing participation for 90 minutes a day\n* New spasticity treatment (pharmacological or Botox)","21 Years",{"count":526,"type":22},96,[84],"The purpose of the study is to explore the feasibility of using a wearable device, called a myoelectric-computer interface (MCI), to improve arm movement in people who have had a stroke.\n\nImpaired arm movement after stroke is caused not just by weakness, but also by impaired coordination between joints due to abnormal co-activation of muscles. These abnormal co-activation patterns are thought to be due to abnormal movement planning.The MCI aims to reduce abnormal co-activation by providing feedback about individual muscle activations.\n\nThis randomized, controlled, blinded study will test the home use of an MCI in chronic and acute stroke survivors.",[26,27],[402],"2026-04-07",{"date":509,"type":42},{"date":534,"type":42},"2018-01-15",{"date":536,"type":22},"2027-04",{"name":538,"class":49},"Northwestern University",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":547,"targetDuration":289,"studyType":23,"phases":4,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":50},"100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222","NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases",{"count":548,"type":22},300,"EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[27,28,248],[552,553,554,555,556],"acute ischemic stroke","noncoding RNA","endovascular treatment","clinical significance","outcome","2026-04-06",{"date":511,"type":42},{"date":560,"type":42},"2020-03-15",{"date":562,"type":22},"2026-12-01",{"name":564,"class":49},"Nanjing First Hospital, Nanjing Medical University",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":82,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":50},"100631931","study-on-the-optimal-head-position-for-patients-with-severe-acute-ischemic-stroke-100631931","NCT07507097","Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke according to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023\": ①Acute onset, ②Focal neurological deficits, with a few having global neurological deficits, ③Imaging shows a corresponding lesion or symptoms\u002Fsigns persist for more than 24 hours, ④Exclusion of non-vascular causes, ⑤Brain CT\u002FMRI excludes cerebral hemorrhage\n3. Meeting the criteria for severe ischemic stroke patients: severe neurological deficits at admission \\[for example, National Institutes of Health Stroke Scale (NIHSS) score≥15\\]\n4. First-time diagnosed ischemic stroke patients who undergo thrombolysis and\u002For thrombectomy reperfusion treatment\n5. Time from onset to randomization within 24 hours\n6. Informed consent obtained and signed by the patient or their family\n\nExclusion Criteria\n\n1. Known pregnancy or breastfeeding, or positive pregnancy test before randomization\n2. Expected survival time less than 3 months (such as with malignant tumors, severe cardiopulmonary diseases, etc)\n3. Already participating in other interventional clinical studies that may affect outcome assessment\n4. Other situations deemed by the investigator as unsuitable for participation in this study or that may pose significant risks to the patient (such as inability to understand and\u002For comply with study procedures and\u002For follow-up due to mental illness, cognitive or emotional disorders)\n5. Presence of brain midline shift or herniation, ventricular mass effect\n6. Patients with limited head elevation (or patients unable to cooperate with postural intervention due to their condition\u002Frecovery needs, etc.)\n7. Presence of respiratory infection symptoms such as fever, cough, or sputum production at the time of admission",{"count":572,"type":22},1508,[84],"Stroke is the second leading cause of death and the third leading cause of disability worldwide, with an increasing incidence. Reperfusion therapy after cerebral ischemia is one of the most practical and effective treatments for ischemic stroke globally. However, the nursing care and management of hemodynamics during the acute phase after reperfusion therapy for ischemic stroke have always been key and challenging aspects of clinical work. Stable hemodynamic status can prevent hypoperfusion or hyperperfusion of brain tissue, reduce damage to the ischemic core and penumbra areas, and consequently decrease cerebral edema, elevated intracranial pressure, and the associated neurological damage and worsening clinical outcomes.\n\nHead positioning, as a simple, economical, and effective adjunctive treatment for managing patients undergoing reperfusion therapy, has gradually received attention. During the acute phase of stroke, brain tissue is in a state of ischemia and hypoxia. Lying flat may increase blood and oxygen supply to the brain tissue, providing a certain degree of protection, but it may also have some impact on swallowing and lung function. Raising the head of the bed can help venous blood return from the head and may reduce cerebral edema to some extent, but it can also affect perfusion of ischemic brain tissue to a certain degree. In the acute phase after successful reperfusion, it remains a clinical challenge to maintain stable cerebral blood supply (hemodynamic stability) through nursing care. Head positioning (lying flat or elevating the head of the bed) is a simple, economical nursing measure that may affect cerebral blood flow. However, for severely affected stroke patients like you, there is no clear international consensus on whether maintaining a flat position (0°) or elevating the head of the bed 30° within the first 24 hours after treatment is more beneficial for long-term recovery. Previous studies have shown inconsistent results, so more rigorous research is needed to answer this question.\n\nThe primary purpose of this study is to determine that a 30° position during the acute phase of severe ischemic stroke is safe. The secondary purpose is to evaluate whether a 30° position in the acute phase improves 90-day outcomes compared to a 0° position (assessed using the modified Rankin Scale).\n\nThis study is a randomized controlled trial. This means you will be randomly assigned (like a coin toss) to one of the following two groups: Experimental group: within 24 hours of admission, maintain the head and bed elevated at 30°. Control group: within 24 hours of admission, remain completely flat (0°). Interventions and methods: Both head positions are commonly used basic nursing measures in neurological intensive care. Lying flat may help increase blood supply to the brain, while elevating the head of the bed may help reduce cerebral edema and the risk of aspiration. This study aims to scientifically compare which angle is better for your long-term recovery. Procedures: Research nurses will use a special angle ruler to ensure your head position is accurate. During the 24-hour intervention, we need you to maintain the assigned position as much as possible. Considering your comfort and necessary medical care (such as back patting and skin inspection), brief interruptions are allowed (no more than three times for the flat position group, with each interruption less than 30 minutes). Legal Compliance: Head positioning management is a routine nursing procedure. This study only conducted standardization and comparative research on it, and did not involve the use of any experimental drugs or high-risk devices. It has passed ethical review.",[270],"2026-03-29",{"date":578,"type":42},"2026-04-02",{"date":580,"type":22},"2026-05-01",{"date":582,"type":22},"2029-04-30",{"name":584,"class":49},"West China Hospital",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":82,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":50},"100582548","virtual-reality-rehabilitation-for-stroke-patients-in-the-hospital-and-at-home-100582548","NCT06864741","Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.","Acute Stroke Rehabilitation Using a Low-cost Virtual Reality Platform: a Pilot Study.","Inclusion Criteria:\n\n* clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by CT or MRI;\n* score between 6 and 40 on Fugl-Meyer Assessment's Upper Limb Extremity Subscore (FM - UE), indicating moderate to severe motor deficit;\n* ability and willingness to provide consent (score of 18 or more on the Montreal Cognitive Assessment) or assent (for scores lower than 18 on MoCA with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient)\n* INPATIENT ARM: less than 5 weeks since stroke onset with admission to Valley Regional Hospital in Kentville, NS, Canada\n* OUTPATIENT ARM: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of Valley Regional Hospital in Kentville, NS, Canada\n\nExclusion Criteria:\n\n* brainstem, cerebellar or bilateral stroke lesion\n* a secondary neurological condition (e.g., Parkinson's disease)\n* musculoskeletal injuries interfering with task performance\n* an uncorrected visual deficit due to stroke or other etiologies\n* apraxia as identified by clinical assessment",{"count":111,"type":22},[84],"The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.\n\nThe main questions it aims to answer are:\n\n* Can VR-based motor therapy improve upper limb motor function compared to standard care?\n* Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?\n\nResearchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.\n\nParticipants will:\n\n* Complete standardized assessments of motor function and quality of life at multiple time points.\n* Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement.\n* Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.\n\nThis study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.",[270],[400,402,597,401],"motor disorder","2026-03-16",{"date":600,"type":42},"2026-03-18",{"date":602,"type":42},"2025-10-15",{"date":604,"type":22},"2027-06",{"name":606,"class":49},"Nova Scotia Health Authority",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":624},"100483689","effective-translation-of-endovascular-thrombectomy-trials-into-real-world-practice-in-the-asia-pacific-100483689","NCT05578300","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific: a Multicenter, Prospective Registry (ENDURE-APAC)","Inclusion Criteria:\n\n* Patient who are over 18 years of age.\n* Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).\n\nExclusion Criteria:\n\n* Patient with isolated vertebral artery occlusion not involving the BA.",{"count":615,"type":22},350,"As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific.\n\nIn this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.",[294,26,27,28,30,221],{"date":600,"type":42},{"date":620,"type":42},"2022-10-21",{"date":622,"type":22},"2032-12-31",{"name":232,"class":49},3,{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":82,"phases":635,"briefSummary":636,"conditions":637,"keywords":638,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":651},"100579561","delay-avoiding-primary-evaluation-for-thrombectomy-of-acute-stroke-patients-with-large-vessel-occlusion-in-the-angiography-suite-100579561","NCT06825897","Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe","Delay Avoiding Primary Evaluation for Thrombectomy for Acute Stroke Patients With Large Vessel Occlusion in the Angiography Suite (DIRECT) Trial","DIRECT","Inclusion Criteria:\n\nTo be eligible for participation in the DIRECT trial, an individual must meet all of the following criteria:\n\n1. Age: ≥ 18 years of age.\n2. Clinical Presentation: Present to a participating TSC with signs or symptoms suggestive of acute LVO stroke.\n3. Stroke Severity: Baseline NIHSS of 10 or higher.\n4. Time since LKW: Time from LKW to arrival at the TSC must be within 7 hours.\n\nAdditional criteria\n\nFor all Interfacility Transfers:\n\n1\\. If imaging was performed at the outside facility, the time from the first imaging to arrival at the thrombectomy center must exceed 90 minutes.\n\nFor all the Conventional Triage Arm, participants must also meet the following criteria:\n\n1. Presence of a qualifying LVO by CTA or MRA imaging; or\n2. For Large Core Patients: Patients with large core infarcts (CT-ASPECT score ≤ 5, DWI-ASPECT score ≤ 5, or infarct volume ≥ 70 cc) will be enrolled, irrespective of treatment decisions regarding embolectomy.\n\nFor all DTAS Arm:\n\n1\\. Patients who do not have LVO occlusions in the angiography suite assessment (ICH, distal occlusions or mimics) will be enrolled, irrespective of treatment decisions regarding embolectomy.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the trial:\n\n1. Time Restrictions: Presentation to a thrombectomy-capable center more than 7 hours from LSW.\n2. Imaging Criteria for Interfacility Transfer Patients: At sites enrolling transfer patients, any patient arriving from an outside hospital with time from imaging study at the presenting hospital to arrival at the TSC not exceeding 90 minutes.\n3. Hemorrhagic Stroke: Presence of intracranial hemorrhage on brain imaging in the conventional strategy as Heidelberg that renders thrombectomy contraindicated.",{"count":634,"type":22},2039,[84],"The purpose of this study is to compare two strategies for treating adults with suspected large vessel occlusion stroke within 7 hours of symptom onset. Researchers will evaluate whether direct transfer to the neurointerventional angiography suite improves recovery and reduces disability compared to the conventional approach of first being evaluated in the emergency department. The study will also assess safety and other health outcomes to guide care for stroke patients.",[27],[639,640,641],"Large Vessel Occlusion","Acute Ischemic Stroke","Pragmatic Clinical Trial","2026-03-11",{"date":644,"type":42},"2026-03-13",{"date":646,"type":42},"2026-01-27",{"date":648,"type":22},"2028-04-30",{"name":650,"class":49},"Santiago Ortega Gutierrez",6]